SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-000313
Filing Date
2021-06-07
Accepted
2021-06-07 08:00:17
Documents
14
Period of Report
2021-06-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K impl-20210607.htm   iXBRL 8-K 60130
2 EX-99.1 impl-20210607ex99_1.htm EX-99.1 275550
3 GRAPHIC img54894287_0.jpg GRAPHIC 3459
  Complete submission text file 0000950170-21-000313.txt   484910

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT impl-20210607_pre.xml EX-101.PRE 11617
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT impl-20210607.xsd EX-101.SCH 2431
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT impl-20210607_lab.xml EX-101.LAB 18297
7 EXTRACTED XBRL INSTANCE DOCUMENT impl-20210607_htm.xml XML 4895
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL NEUROPHARMA INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 21998276
SIC: 2834 Pharmaceutical Preparations